These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9499247)

  • 41. Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation.
    Hou WH; Huang CY; Wang CC; Lan KH; Chen CH; Yu HJ; Liu SP; Lai MK; Pu YS; Cheng JC
    Asian J Androl; 2017; 19(5):596-601. PubMed ID: 27506334
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
    Potters L; Torre T; Ashley R; Leibel S
    J Clin Oncol; 2000 Mar; 18(6):1187-92. PubMed ID: 10715287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low dose rate iridium-192 prostate implantation and external beam irradiation.
    Stromberg J; Martinez A; Benson R; Garton G; Diokno A; Gonzalez J; Zincke H; Schray M; Edmundson G; Brabbins D
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):67-75. PubMed ID: 8270460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy.
    Vicini FA; Kini VR; Spencer W; Diokno A; Martinez AA
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):707-13. PubMed ID: 10098424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
    Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
    Carles J; Gallardo E; Doménech M; Font A; Bellmunt J; Figols M; Mellado B; Sáez MI; Suárez C; Méndez MJ; Maroto P; Luque R; de Portugal T; Aldabo R; Bonfill T; Morales-Barrera R; García J; Maciá S; Maldonado X; Foro P
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):344-352. PubMed ID: 30321689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Adjuvant radiotherapy following radical prostatectomy--results, acute and late toxicity].
    Wiegel T; Bressel M; Baumann M; Schwarz R; Hübener KH
    Strahlenther Onkol; 1993 Mar; 169(3):152-8. PubMed ID: 8465249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
    Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
    Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR; Presti JC; Gill H; Brooks J; Hancock SL
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Combination of radiotherapy and androgen deprivation therapy for localized prostate cancer].
    Hennequin C; Fumagalli I; Martin V; Quero L
    Cancer Radiother; 2017 Oct; 21(6-7):462-468. PubMed ID: 28870416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy.
    Lai PP; Perez CA; Lockett MA
    Int J Radiat Oncol Biol Phys; 1992; 24(3):423-30. PubMed ID: 1399726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
    Morris LM; Izard MA; Wan WY
    Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.